Hi NZT and all,A few questions and comments.Firstly SVN has a 8...

Hi NZT and all,

A few questions and comments.

Firstly SVN has a 8 year royalty stream for Bronchitol and Aridol.Approximately what is that worth to the Company per year ?

According to Peter Molloy Pharmaxis was once worth 739 million in 2007 with it's lead candidate Bronchitol.

PXS-5505 was transferred to SNT from Pharmaxis and renamed SNT-5505. It was discovered I believe in 2019.

Molloy stated that Pharmaxis chased in house commercialization for Bronchitol and it did not end well. Page 154.

CEO GP wishes to target all monetary value in bone marrow cancer. A figure of one billion , also he is not selling the drug in the near term

So a two cent Company with a MC of 20 million $. What am I missing. No wonder the Institutions are all well over this !

So HC members I will place a valuation of a huge number nowhere near the MC. Anyone that gets in here is smartly investing.

Well done LT holders . I can see your spirits pick up given the topline results due your way. 180 days to go.

https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://researchbank.swinburne.edu.au/file/0a7e
e27f-bef3-4a7c-b32d-87e2c3df372f/1/peter_molloy_thesis.pdf&ved=2ahUKEwinisL6152GAxWm4jgGHTwaDGEQFnoECBUQAQ&usg=AOvVaw3IlTbkJcYcupdTz4hTEUGn

https://www.listcorp.com/asx/snt/syntara-limited/news/annual-report-to-shareholders-2789280.html

Kpax